AU2001236716A1 - Antigenic complexes and methods - Google Patents

Antigenic complexes and methods

Info

Publication number
AU2001236716A1
AU2001236716A1 AU2001236716A AU3671601A AU2001236716A1 AU 2001236716 A1 AU2001236716 A1 AU 2001236716A1 AU 2001236716 A AU2001236716 A AU 2001236716A AU 3671601 A AU3671601 A AU 3671601A AU 2001236716 A1 AU2001236716 A1 AU 2001236716A1
Authority
AU
Australia
Prior art keywords
methods
antigenic complexes
antigenic
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236716A
Inventor
Douglas E Brough
Joseph T Bruder
Imre Kovesdi
Duncan L Mcvey
Petrus W Roelvink
Thomas J Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU2001236716A1 publication Critical patent/AU2001236716A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001236716A 2000-02-09 2001-02-07 Antigenic complexes and methods Abandoned AU2001236716A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18128900P 2000-02-09 2000-02-09
US60181289 2000-02-09
US09/617,569 US6756044B1 (en) 2000-02-09 2000-07-17 Antigenic complexes and methods
US09617569 2000-07-17
PCT/US2001/003892 WO2001058478A1 (en) 2000-02-09 2001-02-07 Antigenic complexes and methods

Publications (1)

Publication Number Publication Date
AU2001236716A1 true AU2001236716A1 (en) 2001-08-20

Family

ID=26877051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236716A Abandoned AU2001236716A1 (en) 2000-02-09 2001-02-07 Antigenic complexes and methods

Country Status (4)

Country Link
US (1) US6756044B1 (en)
EP (1) EP1259256A1 (en)
AU (1) AU2001236716A1 (en)
WO (1) WO2001058478A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
JP4516748B2 (en) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー Packaging immunostimulatory substances in virus-like particles: preparation and use
JP4360906B2 (en) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles
WO2003063770A2 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2003251604A1 (en) * 2002-06-26 2004-01-19 F. C. Thomas Allnutt Viruses and virus-like particles for multiple antigen and target display
CA2517675A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2006305754A1 (en) * 2005-10-28 2007-05-03 Centocor, Inc. Use of B cell expansion agents in generating antibodies
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US7998485B2 (en) * 2006-05-11 2011-08-16 Universiteit Gent Sialoadhesin-related compositions and methods
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
MX2011009597A (en) 2009-03-17 2012-05-29 Glaxosmithkline Biolog Sa Improved detection of gene expression.
SG10201913784YA (en) 2012-01-25 2020-03-30 Dnatrix Inc Biomarkers and combination therapies using oncolytic virus and immunomodulation
AU2013214776B2 (en) 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714374A (en) 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
WO1998015638A2 (en) 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
JP5546084B2 (en) 1998-05-26 2014-07-09 オプサニテクス エルエルシー Compositions and methods for modulating an immune response to an antigen
EP1000628A1 (en) 1998-09-28 2000-05-17 Fondation Mondiale Recherche et Prevention SIDA Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine

Also Published As

Publication number Publication date
WO2001058478A1 (en) 2001-08-16
EP1259256A1 (en) 2002-11-27
US6756044B1 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
AU2001275441A1 (en) Filter arrangement and methods
AU2001286419A1 (en) Endourethral device and method
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001236716A1 (en) Antigenic complexes and methods
AU2002211717A1 (en) Stresscopins and their uses
IL153539A0 (en) Protein complexes and methods for the preparation thereof
AU2001279850A1 (en) Method and arrangement for studsystem
AU2001243394A1 (en) Compounds and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001261005A1 (en) Immune mediators and related methods
AUPQ872300A0 (en) Compounds and methods
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU1083501A (en) Antibiotic-metal complex and methods
AU2001278951A1 (en) Compounds and methods
AU2001266176A1 (en) Methods
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2001210572A1 (en) Ornament
AU2002256556A1 (en) Sea-trosy and related methods
AU2001282521A1 (en) OCT preparations
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2002235277A1 (en) Compounds and methods
AU2001250536A1 (en) Methods
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof